ArticleKidney & blood pressure research2026
Long-Term Betaine Supplementation Increases Creatinine Clearance and Upregulates MAS and AT2 Receptor Expression in Spontaneously Hypertensive Rat Kidneys.
Article in Kidney & blood pressure research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHypertension contributes to renal dysfunction, partly through dysregulation of the renin-angiotensin system (RAS). Betaine, an osmolyte that helps maintain medullary osmotic gradients, has demonstrated renoprotective effects in models of nephrotoxicity. Previously, we showed that acute betaine administration increases diuresis - more pronounced in spontaneously hypertensive rats (SHRs) than in normotensive Wistar-Kyoto rats - without affecting blood pressure. In this study, we investigated the effects of chronic betaine supplementation on SHR renal function.
methodsSix-week-old male SHRs received either 0.5% betaine in drinking water or tap water for 16 weeks. Hemodynamics, serum and urine biochemistry, and renal mRNA expression of RAS components and betaine transporters (SLC6A12, SLC6A20) were assessed.
resultsBetaine-treated SHRs demonstrated higher creatinine clearance without significant changes in arterial blood pressure. Renal expression of angiotensinogen and AT1B receptor was reduced, while MAS and AT2 receptor expression increased. Transporter expression showed region-specific regulation: cortical SLC6A20 and medullary SLC6A12 were lower in betaine-treated rats, whereas medullary SLC6A20 was higher.
conclusionChronic betaine supplementation was associated with increased creatinine clearance and a renal RAS mRNA profile shifted toward MAS and AT2 receptor predominance. These findings support further investigation of betaine as a potential strategy for early prevention of hypertensive kidney injury. However, direct evidence of improved glomerular filtration and functional activation of protective RAS pathways is still needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.